Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last1,981 to 2,000 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Universal PrEP Counselling vs Targeted PrEP Clinics: PrEP Use | 397 of 2,250 323 of 2,197 | 2.9 points 0.8 to 5.1 | 4,447 | NCT03070600 PrEP Implementation for Mothers in Antenatal Care |
| Universal PrEP Counselling vs Targeted PrEP Clinics: deaths from any cause | 2 of 2,250 2 of 2,197 | -0.0 points -0.3 to 0.2 | 4,447 | NCT03070600 PrEP Implementation for Mothers in Antenatal Care |
| Universal PrEP Counselling vs Targeted PrEP Clinics: serious adverse events | 132 of 2,250 118 of 2,197 | 0.5 points -0.9 to 1.9 | 4,447 | NCT03070600 PrEP Implementation for Mothers in Antenatal Care |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): Incidence of Adverse Events for Each Treatment | 416 of 2,227 429 of 2,219 | -0.7 points -3.0 to 1.7 | 4,446 | NCT02135419 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): deaths from any cause | 55 of 2,227 48 of 2,219 | 0.3 points -0.6 to 1.2 | 4,446 | NCT02135419 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): serious adverse events | 370 of 2,227 375 of 2,219 | -0.3 points -2.5 to 1.9 | 4,446 | NCT02135419 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions |
| Mindfulness-Based Cognitive Therapy vs Brief Mindfulness: serious adverse events | 30 of 2,220 31 of 2,192 | -0.1 points -0.8 to 0.6 | 4,412 | NCT03844321 Healthy Mind Healthy You: A Study of Mindfulness |
| Colchicine vs Placebo: deaths from any cause | 5 of 2,195 9 of 2,217 | -0.2 points -0.6 to 0.2 | 4,412 | NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Colchicine vs Placebo: serious adverse events | 108 of 2,195 139 of 2,217 | -1.3 points -2.7 to 0.0 | 4,412 | NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Chemo and Endocrine Therapy vs Endocrine Therapy Alone: serious adverse events | 14 of 2,062 9 of 2,342 | 0.3 points -0.1 to 0.8 | 4,404 | NCT01272037 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer |
| Canagliflozin 100 mg vs Placebo: deaths from any cause | 164 of 2,200 193 of 2,197 | -1.3 points -3.0 to 0.3 | 4,397 | NCT02065791 Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy |
| Canagliflozin 100 mg vs Placebo: serious adverse events | 737 of 2,200 806 of 2,197 | -3.2 points -6.0 to -0.4 | 4,397 | NCT02065791 Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy |
| MenHibrix Group vs ActHIB Group: serious adverse events | 157 of 3,278 48 of 1,113 | 0.5 points -1.0 to 1.8 | 4,391 | NCT00345579 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age |
| Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation | 381 of 2,200 440 of 2,172 | -2.9 points -5.3 to -0.6 | 4,372 | NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. |
| XAGRID vs Other (Cytoreductives): Number of Participants With Suspected Serious Adverse Reaction (SSAR) Events | 37 of 1,300 70 of 3,069 | 0.6 points -0.4 to 1.7 | 4,369 | NCT00567502 Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments |
| XAGRID vs Other (Cytoreductives): serious adverse events | 37 of 1,300 70 of 3,069 | 0.6 points -0.4 to 1.7 | 4,369 | NCT00567502 Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin | 45 of 2,184 123 of 2,167 | -3.6 points -4.8 to -2.5 | 4,351 | NCT00141102 Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis |
| Vitamins vs Placebo: Analysis of Primary Composite Outcome in Participants Randomized Before the 13th Week of Pregnancy | 144 of 2,181 127 of 2,162 | 0.7 points -0.7 to 2.2 | 4,343 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Blood Transfusion | 138 of 2,164 140 of 2,164 | -0.1 points -1.6 to 1.4 | 4,328 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| Universal PrEP Counselling vs Targeted PrEP Clinics: Preterm Birth | 506 of 2,205 309 of 2,101 | 8.2 points 5.9 to 10.6 | 4,306 | NCT03070600 PrEP Implementation for Mothers in Antenatal Care |
Code
curl "https://conductscience.org/api/comparisons/v1?page=100"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=100
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03070600-689938d0",
"title": "Universal PrEP Counselling vs Targeted PrEP Clinics: PrEP Use",
"summary": "397 of 2250 against 323 of 2197; risk difference 2.9 points, 95% interval 0.8 to 5.1; NCT03070600, PrEP Implementation for Mothers in Antenatal Care",
"record": "/library/comparisons/NCT03070600-689938d0",
"nct_id": "NCT03070600",
"kind": "outcome",
"participants": 4447,
"risk_difference": {
"value": 0.0294257826328832,
"lower": 0.007773936856835039,
"upper": 0.051037034672771195
},
"group_1": "397 of 2,250",
"group_2": "323 of 2,197",
"difference": "2.9 points",
"interval": "0.8 to 5.1",
"trial_title": "PrEP Implementation for Mothers in Antenatal Care"
},
{
"id": "NCT03070600-deaths",
"title": "Universal PrEP Counselling vs Targeted PrEP Clinics: deaths from any cause",
"summary": "2 of 2250 against 2 of 2197; risk difference -0.0 points, 95% interval -0.3 to 0.2; NCT03070600, PrEP Implementation for Mothers in Antenatal Care",
"record": "/library/comparisons/NCT03070600-deaths",
"nct_id": "NCT03070600",
"kind": "deaths",
"participants": 4447,
"risk_difference": {
"value": -0.000021443382390127922,
"lower": -0.002509450519323683,
"upper": 0.0024162514123507537
},
"group_1": "2 of 2,250",
"group_2": "2 of 2,197",
"difference": "-0.0 points",
"interval": "-0.3 to 0.2",
"trial_title": "PrEP Implementation for Mothers in Antenatal Care"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=101",
"request_id": "k2iyU50zhsgjMx2k"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant